No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Li Tao, the Secretary of the Board of Directors and Chief Financial Officer of Bid Pharma (688073.SH), has resigned.
Bid Medicine (688073.SH) announced that the company's Board of Directors recently received a report from the company's Board of Directors Secretary, Financial Department...
Bid Pharma (688073.SH): No Trade buyback has been conducted.
Glory Financial reported on March 4th that Bid Pharmaceuticals (688073.SH) announced that as of the end of February 2025, the company has not conducted any Trade buybacks.
Bide Pharmaceuticals: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
Bid Pharma (688073.SH): The net income for 2024 is 0.12 billion yuan, a year-on-year growth of 12.07%.
On February 25, Glonghui announced that Bid Medical (688073.SH) released its performance report for the fiscal year 2024. During the reporting period, the company achieved revenue of 1,102.0103 million yuan, an increase of 0.93% year-on-year; the net income attributable to the parent company's owners was 122.7925 million yuan, an increase of 13.2207 million yuan, or 12.07%; the net income attributable to the parent company's owners, excluding non-recurring gains and losses, was 108.7928 million yuan, a decrease of 13.7173 million yuan, or a decline of 11.20%. During the reporting period, the changes in the macroeconomic environment, down
Are Bide Pharmatech Co., Ltd.'s (SHSE:688073) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?